Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: REGN17235 · Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation Trial sites expanded: 0 → 3 locations
- Minor: COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors · Diabetes Trial sites expanded: 7 → 10 locations
- Minor: SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) Trial sites expanded: 24 → 27 locations
- Minor: Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib · High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Trial sites expanded: 258 → 262 locations
- Minor: Non-Interventional Study · Limbal Stem Cell Deficiency Trial sites expanded: 8 → 21 locations
- Minor: Drug-Eluting Registry · Real-World Treatment of Lesions in the Peripheral Vasculature Trial sites expanded: 86 → 89 locations
- Minor: Tornier Perform™ Reversed Monopost Study Trial sites expanded: 0 → 3 locations
- Minor: Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery Trial sites expanded: 4 → 11 locations
- Minor: Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer · a Weakened Immune System Trial sites expanded: 57 → 60 locations
- Minor: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Trial sites expanded: 22 → 27 locations
- Minor: Experimental Approach · Plasma Cell Leukemia, The QUANTUM Trial Trial sites expanded: 11 → 14 locations
- Minor: Addition of Iberdomide to Therapy · Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Trial sites expanded: 3 → 7 locations
- Minor: Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Trial sites expanded: 149 → 152 locations
- Minor: Histotripsy x Pancreatic Cancer Enrollment increased: 20 → 25 participants
- Minor: Use of Ultrasound for Early Identification of Patients at Risk of Swallowing Disorders Acquired in the ICU Enrollment increased: 100 → 110 participants
- Minor: Vanguard Study: Testing a New Way to Screen for Cancer Trial sites expanded: 44 → 49 locations
- Minor: Corticosteroids in Hyperinflammatory Phenotype of Critical Illness Trial sites expanded: 1 → 11 locations
- Minor: BEACON-AA · Apixaban With or Without Clopidogrel in Stroke · Atrial Fibrillation and Cerebral Atherosclerosis Trial sites expanded: 0 → 21 locations
- Minor: Progressive Supranuclear Palsy Clinical Trial Platform Trial sites expanded: 21 → 24 locations
- Minor: Effective and Safe Odronextamab is Compared to Standard of Care · Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Study completion moved earlier from May 29, 2029 to May 29, 2028
- Minor: Guselkumab Subcutaneous Therapy · Moderately to Severely Active Crohn's Disease Study completion moved earlier from Oct 30, 2028 to Mar 27, 2028
- Minor: ORJ-001 · IPF Start date pushed from Oct 2026 to Nov 2026
- Minor: SPY072 · Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) Start date changed from estimate of Sep 2026 to Oct 6, 2026
- Minor: National Registry of Noonan Syndrome Trial sites reduced: 35 → 13 locations
- Minor: Food Effect of UBT48128 Tablets in Healthy Participants Study completion pushed from Dec 30, 2026 to Mar 31, 2027
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates